Teva Announces Additional Regulatory Exclusivity for TREANDA ... Lifescience-online TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Important Safety Information. |
